Small Is Beautiful: Insulin-Like Growth Factors and Their Role in Growth, Development, and Cancer
Small Is Beautiful: Insulin-Like Growth Factors and Their Role in Growth, Development, and Cancer
复制标题
DOI：
10.1200/jco.2009.27.5040
复制
发表时间：
2010-11-20
影响因子：
45.3
通讯作者：
Maki, Robert G.
中科院分区：
文献类型：
--
作者：
Maki, Robert G.
胰岛素样生长因子是50多年前发现的，作为生长激素的介质，影响骨和骨骼肌的生长和分化。对胰岛素样生长因子在癌症中的作用的兴趣在20世纪90年代达到高峰，然后逐渐减弱，直到过去5年中可获得阻断胰岛素样生长因子1受体的单克隆抗体和小分子。在这篇文章中，我们回顾了胰岛素样生长因子的历史及其在生长，发育，生物体存活和癌症中的作用，包括上皮癌和肉瘤。最近的事态发展，有关I期至II期临床试验的药物进行了讨论，以及潜在的研究，以考虑在未来，鉴于缺乏疗效的一个这样的单克隆抗体与细胞毒化疗相结合的一线研究转移性非小细胞肺腺癌。当将这些药物与已经观察到交叉耐药性的其他细胞信号传导途径的抑制剂组合时，预期这些药物在临床上取得更大的成功。J Clin Oncol 28：4985-4995。(C)2010年美国临床肿瘤学会
Insulin-like growth factors were discovered more than 50 years ago as mediators of growth hormone that effect growth and differentiation of bone and skeletal muscle. Interest of the role of insulin-like growth factors in cancer reached a peak in the 1990s, and then waned until the availability in the past 5 years of monoclonal antibodies and small molecules that block the insulin-like growth factor 1 receptor. In this article, we review the history of insulin-like growth factors and their role in growth, development, organism survival, and in cancer, both epithelial cancers and sarcomas. Recent developments regarding phase I to II clinical trials of such agents are discussed, as well as potential studies to consider in the future, given the lack of efficacy of one such monoclonal antibody in combination with cytotoxic chemotherapy in a first-line study in metastatic non-small-cell lung adenocarcinoma. Greater success with these agents clinically is expected when combining the agents with inhibitors of other cell signaling pathways in which cross-resistance has been observed.J Clin Oncol 28:4985-4995. (C) 2010 by American Society of Clinical Oncology